Kathryn A. Gold

Oncology

3855 Health Sciences Dr
La Jolla, CA 92093

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 57 publications

BIO26-035: Validation of an Electronic Health Record Phenotype for Advanced Solid Cancer Across Five University of California Health Systems.

BIO26-035: Validation of an Electronic Health Record Phenotype for Advanced Solid Cancer Across Five University of California Health Systems.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 16, 2026

BIO26-035: MTAP Deficiency in Thoracic Oncology: Bridging Genomic Loss, Survival Deficits, and Immunosuppressive Microenvironments.

BIO26-035: MTAP Deficiency in Thoracic Oncology: Bridging Genomic Loss, Survival Deficits, and Immunosuppressive Microenvironments.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 30, 2026

NCCN Guidelines® Insights: Small Cell Lung Cancer, Version 2.2026.

NCCN Guidelines® Insights: Small Cell Lung Cancer, Version 2.2026.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: February 11, 2026

Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy.

Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 24, 2025

Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC.

Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: October 11, 2023

Spatial PD-L1, immune-cell microenvironment, and genomic copy-number alteration patterns and drivers of invasive-disease transition in prospective oral precancer cohort.

Spatial PD-L1, immune-cell microenvironment, and genomic copy-number alteration patterns and drivers of invasive-disease transition in prospective oral precancer cohort.

Journal: Cancer

Published: September 16, 2022

A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma.

A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma.

Journal: Oral oncology

Published: August 03, 2022

Comparison of Early- and Late-Stage Breast and Colorectal Cancer Diagnoses During vs Before the COVID-19 Pandemic.

Comparison of Early- and Late-Stage Breast and Colorectal Cancer Diagnoses During vs Before the COVID-19 Pandemic.

Journal: JAMA network open

Published: February 15, 2022

Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: December 13, 2021

A framework and road map for rapid start-up and completion of a COVID-19 vaccine trial: A single clinical trial site experience.

A framework and road map for rapid start-up and completion of a COVID-19 vaccine trial: A single clinical trial site experience.

Journal: Journal of clinical and translational science

Published: October 05, 2021

Clinicopathologic and molecular characteristics of EGFR-mutant lung adenocarcinomas that transform to small cell lung cancer after TKI therapy.

Clinicopathologic and molecular characteristics of EGFR-mutant lung adenocarcinomas that transform to small cell lung cancer after TKI therapy.

Journal: Translational lung cancer research

Published: August 20, 2021

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer.

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer.

Journal: Cancer discovery

Published: June 03, 2021

Showing 1-12 of 57

Last Updated: 09/26/2026